Clifford Chance has advised the underwriters led by Credit Suisse and China International Capital Corporation on Genetron Holdings’ US$256 million SEC-registered IPO of American Depositary Shares and listing on Nasdaq. Davis Polk advised Genetron Holdings Limited on the offering.
Genetron is a leading and fast-growing precision oncology company in China, covering the full cycle on cancer care, from early screening to diagnosis and treatment recommendations and monitoring and continuous care. Genetron offered 16 million ADSs, an upsizing from 13 million, at an offering price of US$16, well above the higher end of the price range (US$13.50). According to Forbes China, this offering is the largest ever precision oncology medicine company IPO.
Fang was supported by partners Jonathan Zonis (Picture – capital markets), Philip Wagman (tax) and Jefferey LeMaster (regulatory) in New York, and senior associates Yuling Geng and Matt Worden, and associates James Zhang, Tao Yang, Dan Borchert and David G Adams.
Davis Polk advised Genetron Holdings Limited with a corporate team which included partners Li He and James C. Lin, counsel – registered foreign lawyer Xuelin (Steve) Wang and registered foreign lawyer Xin (Sheen) Xu. Counsel Alon Gurfinkel and associate Omer Harel provided tax advice. Associate J. Taylor Arabian provided 1940 Act advice.
Involved fees earner: David Adams – Clifford Chance; Dan Borchert – Clifford Chance; Yuling Geng – Clifford Chance; Jefferey LeMaster – Clifford Chance; Philip Wagman – Clifford Chance; Matt Worden – Clifford Chance; Tao Yang – Clifford Chance; James Zhang – Clifford Chance; Jonathan Zonis – Clifford Chance; Taylor Arabian – Davis Polk & Wardwell; Alon Gurfinkel – Davis Polk & Wardwell; Omer Harel – Davis Polk & Wardwell; Li He – Davis Polk & Wardwell; James Lin – Davis Polk & Wardwell; Xuelin Wang – Davis Polk & Wardwell; Xin Xu – Davis Polk & Wardwell;